Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
Pictured: Eli Lilly's biotechnology center in San Diego, California/iStock, JHVEPhoto Eli Lilly on Wednesday released topline data from the Phase III SURMOUNT-OSA study, which showed that its top-selling weight-loss drug Zepbound (tirzepatide) …